Our Clinical Development Progress

MapLight has already brought two product candidates into the clinic, with more on the horizon. Focused on solutions that serve populations currently struggling with either no treatment options or limited options with significant safety liabilities, MapLight’s initial product candidates are aimed at safely targeting key symptoms of Autism Spectrum Disorder, Schizophrenia, Alzheimer’s Disease Psychosis, and Parkinson’s Disease.